Organon & Company
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.13%.
Did OGN Beat Earnings? Q3 2025 Results
Organon navigated a turbulent third quarter under interim leadership, reporting Q3 2025 revenue of $1.60 billion and earnings per share of $1.01 as the women's health and pharmaceutical company managed through a leadership transition tied to an Audit Committee investigation into its wholesaler sales practices. The standout performer was the Biosimilars franchise, which grew 19% driven by strong Hadlima uptake and favorable tender timing, though that momentum was offset by a 9% ex-FX decline in Nexplanon, the company's largest single product, as reduced U.S. government program funding weighed on demand. GAAP gross margin contracted to 53.5% from 58.3% a year ago due to one-time manufacturing costs, while adjusted EBITDA margin expanded to 32.3% from 29.0%, reflecting a 14% reduction in non-GAAP operating expenses. Looking ahead, Organon trimmed its full-year 2025 revenue guidance to $6.20 billion–$6.25 billion and narrowed adjusted EBITDA margin guidance to approximately 31.0%, while a planned divestiture of the Jada system for up to $465 million signals a strategic pivot toward reducing debt and refocusing the portfolio.
- Strong Biosimilars growth of 19% driven by Hadlima uptake and favorable Ontruzant tender timing
- 14% reduction in non-GAAP operating expenses drove Adjusted EBITDA margin expansion to 32.3%
- Contributions from newly acquired Vtama and Emgality partially offsetting Established Brands headwinds
- Nexplanon decline of 9% ex-FX due to decreased U.S. government program funding
“I am humbled to be working alongside our talented team during this pivotal time for Organon. We are harnessing the company's many strengths, including a diverse portfolio that we expect will generate more than $900 million in free cash flow before one-time costs this year. We also remain committed to exercising cost discipline and reducing our debt burden proactively, where possible. These actions will create additional balance sheet capacity, positioning us to pursue future growth opportunities in women's health and further our mission to deliver impactful medicines and solutions for a healthier every day.”
Organon CEO, on the earnings call
Forward Guidance & Outlook
Organon lowered its full-year 2025 revenue guidance to $6.200 billion–$6.250 billion (from $6.275 billion–$6.375 billion), representing nominal revenue decline of (3.2%)–(2.4%) and ex-FX revenue decline of (3.7%)–(3.1%). FX translation impact shifted from ~$50 million headwind to ~$35–$45 million tailwind. Adjusted EBITDA margin guidance was lowered to approximately 31.0% (from 31.0%–32.0%). Adjusted gross margin (60.0%–61.0%), SG&A (mid 20% range), R&D (upper single-digit), interest (~$510 million), depreciation (~$135 million), effective non-GAAP tax rate (22.5%–24.5%), and fully diluted shares (~263 million) were all unchanged. The company expects more than $900 million in free cash flow before one-time costs for 2025.
OGN YoY Financials
OGN Revenue by Segment
OGN Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.